RESUMEN
The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent mpox during the 2022 global outbreak. This vaccine was initially approved for mpox based on its reported immunogenicity (from phase I/II trials) and effectiveness in animal models, rather than evidence of clinical efficacy. However, no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. We find that delaying the second dose of MVA-BN vaccination will provide more durable protection and may be optimal in an outbreak with limited vaccine stock. Although further work is required to validate this correlate, this study provides a quantitative evidence-based approach for using antibody measurements to predict the effectiveness of mpox vaccination.
Asunto(s)
Vacuna contra Viruela , Eficacia de las Vacunas , Animales , Humanos , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/sangre , Ensayo de Inmunoadsorción Enzimática , Vacuna contra Viruela/inmunología , Vacuna contra Viruela/administración & dosificación , Vacunación/métodos , Vaccinia/inmunología , Vaccinia/prevención & control , Monkeypox virusRESUMEN
BACKGROUND: In male dogs, uroepithelial cancers include invasive urothelial carcinoma (iUC) and prostate carcinoma (PCA). The inability to distinguish iUC involving the prostate from PCA results in indiscriminate clinical management strategies that could be suboptimal as first-line chemotherapy for iUC (cisplatin) and PCA (docetaxel) differ in people. Prostate specific membrane antigen (PSMA) is a transmembrane protein, and its overexpression has been identified in human prostate carcinoma and neovasculature associated with solid tumor growth. This study investigates whether differential PSMA expression exists between presumptive canine iUC and PCA among cell lines and archived patient samples, which might allow for improved accuracy in disease-based stratification and optimal chemotherapy selection. Additionally, in vitro sensitivities of reported canine iUC and PCA cell lines to uroepithelial directed chemotherapeutic agents were characterized. RESULTS: Normalized PSMA gene and protein expressions were not significantly different between 5 iUC and 4 PCA cell lines. PSMA protein expression was uniformly observed in uroepithelial cancers regardless of anatomic origin from archived patient samples, further confirming that PSMA cannot differentiate iUC from PCA. In vitro sensitivity of cell lines to uroepithelial directed chemotherapeutics revealed that vinblastine exerted the broadest cytotoxic activity. CONCLUSIONS: Differential expression of PSMA was not identified between canine iUC and PCA cell lines or archived patient samples, and PSMA alone cannot be used for disease stratification. Nonetheless given its conserved overexpression, PSMA may be a targetable surface marker for both canine iUC and PCA. Lastly, in uroepithelial carcinomas, vinblastine might exert the broadest anticancer activity regardless of cellular origin.
Asunto(s)
Carcinoma de Células Transicionales , Enfermedades de los Perros , Neoplasias de la Próstata , Neoplasias de la Vejiga Urinaria , Humanos , Masculino , Perros , Animales , Carcinoma de Células Transicionales/metabolismo , Carcinoma de Células Transicionales/veterinaria , Neoplasias de la Vejiga Urinaria/metabolismo , Neoplasias de la Vejiga Urinaria/veterinaria , Vinblastina/uso terapéutico , Antígenos de Superficie , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/veterinaria , Próstata/metabolismo , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/tratamiento farmacológico , Enfermedades de los Perros/genéticaRESUMEN
A fundamental question crucial to surface-enhanced spatially offset Raman spectroscopy (SESORS) imaging and implementing it in a clinical setting for in vivo diagnostic purposes is whether a SESORS image can be used to determine the exact location of an object within tissue? To address this question, multiple experimental factors pertaining to the optical setup in imaging experiments using an in-house-built point-collection-based spatially offset Raman spectroscopy (SORS) system were investigated to determine those critical to the three-dimensional (3D) positioning capability of SESORS. Here, we report the effects of the spatial offset magnitude and geometry on locating nanoparticles (NPs) mixed with silica powder as an imaging target through tissue and outline experimental techniques to allow for the correct interpretation of SESORS images to ascertain the correct location of NPs in the two-dimensional x, y-imaging plane at depth. More specifically, the effect of "linear offset-induced image drag" is presented, which refers to a spatial distortion in SESORS images caused by the magnitude and direction of the linear offset and highlight the need for an annular SORS collection geometry during imaging to neutralize these asymmetric effects. Additionally, building on these principles, the concept of "ratiometric SESORS imaging" is introduced for the location of buried inclusions in three dimensions. Together these principles are vital in developing a methodology for the location of surface-enhanced Raman scattering-active inclusions in three dimensions. This approach utilizes the relationship between the magnitude of the spatial offset, the probed depth, and ratiometric analysis of the NP and tissue Raman intensities to ultimately image and spatially discriminate between two distinct NP flavors buried at different depths within a 3D model for the first time. This research demonstrates how to accurately identify multiple objects at depth in tissue and their location using SESORS which addresses a key capability in moving SESORS closer to use in biomedical applications.
Asunto(s)
Nanopartículas , Espectrometría Raman , Nanopartículas/química , Espectrometría Raman/métodosRESUMEN
The blood-brain barrier (BBB) presents a major hurdle in the development of central nervous system (CNS) active therapeutics, and expression of the P-glycoprotein (P-gp) efflux transporter at the blood-brain interface further impedes BBB penetrance of most small molecules. Designing efflux liabilities out of compounds can be laborious, and there is currently no generalizable approach to directly transform periphery-limited agents to ones active in the CNS. Here, we describe a target-agnostic, prospective assessment of P-gp efflux using diverse compounds. Our results demonstrate that reducing the molecular size or appending a carboxylic acid in many cases enables evasion of P-gp efflux in cell-based experiments and in mice. These strategies were then applied to transform a periphery-limited V600EBRAF inhibitor, dabrafenib, into versions that possess potent and selective anti-cancer activity but now also evade P-gp-mediated efflux. When compared to dabrafenib, the compound developed herein (everafenib) has superior BBB penetrance and superior efficacy in an intracranial mouse model of metastatic melanoma, suggesting it as a lead candidate for the treatment of melanoma metastases to the brain and gliomas with BRAF mutation. More generally, the results described herein suggest the actionability of the trends observed in these target-agnostic efflux studies and provide guidance for the conversion of non-BBB-penetrant drugs into versions that are BBB-penetrant and efficacious.
Asunto(s)
Melanoma , Proteínas Proto-Oncogénicas B-raf , Subfamilia B de Transportador de Casetes de Unión a ATP/metabolismo , Subfamilia B de Transportador de Casetes de Unión a ATP/uso terapéutico , Animales , Barrera Hematoencefálica/metabolismo , Melanoma/metabolismo , Ratones , Estudios Prospectivos , Inhibidores de Proteínas Quinasas/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/uso terapéuticoRESUMEN
Actors are required to engage in multimodal modulations of their body, face, and voice in order to create a holistic portrayal of a character during performance. We present here the first trimodal analysis, to our knowledge, of the process of character portrayal in professional actors. The actors portrayed a series of stock characters (e.g., king, bully) that were organized according to a predictive scheme based on the two orthogonal personality dimensions of assertiveness and cooperativeness. We used 3D motion capture technology to analyze the relative expansion/contraction of 6 body segments across the head, torso, arms, and hands. We compared this with previous results for these portrayals for 4 segments of facial expression and the vocal parameters of pitch and loudness. The results demonstrated significant cross-modal correlations for character assertiveness (but not cooperativeness), as manifested collectively in a straightening of the head and torso, expansion of the arms and hands, lowering of the jaw, and a rise in vocal pitch and loudness. These results demonstrate what communication theorists refer to as "multichannel reinforcement". We discuss this reinforcement in light of both acting theories and theories of human communication more generally.
Asunto(s)
Voz , Cara , Expresión Facial , Humanos , OcupacionesRESUMEN
In dogs, primary bone tumors can be difficult to distinguish with histopathology. Of those tumors, osteosarcoma (OSA) is the most common and aggressive. In this study, 4 immunohistochemistry markers-alkaline phosphatase (ALP), osteonectin (ON), osteopontin (OP), and runx2-were evaluated for their ability to distinguish OSA from other primary bone tumors. The 42 formalin-fixed, paraffin-embedded, primary canine bone tumors included 15 OSAs, 8 chondrosarcomas, 11 fibrosarcomas, and 8 histiocytic sarcomas. All 4 antibodies were highly sensitive for detection of osteosarcoma. ALP was the most sensitive at 100% and runx2 the most specific at 78%. Running ALP and runx2 in series resulted in a sensitivity of 87% and a specificity of 85%. This combination of immunomarkers resulted in a diagnostic panel for distinguishing osteosarcoma from other primary bone tumors.
Asunto(s)
Neoplasias Óseas , Enfermedades de los Perros , Osteosarcoma , Animales , Perros , Fosfatasa Alcalina , Neoplasias Óseas/diagnóstico , Neoplasias Óseas/patología , Neoplasias Óseas/veterinaria , Colorantes , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/patología , Osteosarcoma/diagnóstico , Osteosarcoma/patología , Osteosarcoma/veterinariaRESUMEN
Glioblastoma (GBM) is the most lethal primary brain tumor. Currently, frontline treatment for primary GBM includes the DNA-methylating drug temozolomide (TMZ, of the imidazotetrazine class), while the optimal treatment for recurrent GBM remains under investigation. Despite its widespread use, a majority of GBM patients do not respond to TMZ therapy; expression of the O6-methylguanine DNA methyltransferase (MGMT) enzyme and loss of mismatch repair (MMR) function as the principal clinical modes of resistance to TMZ. Here, we describe a novel imidazotetrazine designed to evade resistance by MGMT while retaining suitable hydrolytic stability, allowing for effective prodrug activation and biodistribution. This dual-substituted compound, called CPZ, exhibits activity against cancer cells irrespective of MGMT expression and MMR status. CPZ has greater blood-brain barrier penetrance and comparable hematological toxicity relative to TMZ, while also matching its maximum tolerated dose in mice when dosed once-per-day over five days. The activity of CPZ is independent of the two principal mechanisms suppressing the effectiveness of TMZ, making it a promising new candidate for the treatment of GBM, especially those that are TMZ-resistant.
Asunto(s)
Neoplasias Encefálicas , Glioblastoma , Animales , Antineoplásicos Alquilantes/farmacología , Antineoplásicos Alquilantes/uso terapéutico , Neoplasias Encefálicas/metabolismo , Técnicas de Cultivo de Célula , Línea Celular Tumoral , Resistencia a Antineoplásicos , Glioblastoma/tratamiento farmacológico , Glioblastoma/metabolismo , Humanos , Ratones , Temozolomida/farmacología , Temozolomida/uso terapéutico , Distribución TisularRESUMEN
A model for the prediction of the depth of two 'flavours' of surface enhanced Raman scattering (SERS) active nanotags embedded within porcine tissue is demonstrated using ratiometric analysis. Using a handheld spatially offset Raman (SORS) instrument, SESORS signals could be detected from nanotags at depths down to 48 mm for the first time using a backscattering SORS geometry.
RESUMEN
Actors make modifications to their face, voice, and body to match standard gestural conceptions of the fictional characters they are portraying during stage performances. However, the gestural manifestations of acting have not been quantified experimentally, least of all in group-level analyses. To quantify the facial correlates of character portrayal in professional actors for the first time, we had 24 actors portray a contrastive series of nine stock characters (e.g., king, bully, lover) that were organised according to a predictive scheme based on the two statistically independent personality dimensions of assertiveness (i.e., the tendency to satisfy personal concerns) and cooperativeness (i.e., the tendency to satisfy others' concerns). We used three-dimensional motion capture to examine changes in facial dimensions, with an emphasis on the relative expansion/contraction of four facial segments related to the brow, eyebrows, lips, and jaw, respectively. The results demonstrated that expansions in both upper- and lower-facial segments were related to increases in the levels of character cooperativeness, but not assertiveness. These findings demonstrate that actors reliably manipulate their facial features in a contrastive manner to differentiate characters based on their underlying personality traits.
Asunto(s)
Cara , Voz , Emociones , Expresión Facial , Gestos , HumanosRESUMEN
External beam radiotherapy is indicated in approximately 50-60% of human cancer patients. The prescribed dose of ionizing radiation that can be delivered to a tumor is determined by the sensitivity of the normal surrounding tissues. Despite dose intensification provided by highly conformal radiotherapy, durable locoregional tumor control remains a clinical barrier for recalcitrant tumor histologies, and contributes to cancer morbidity and mortality. Development of target-based radiosensitization strategies that selectively sensitizes tumor tissue to ionizing radiation is expected to improve radiotherapy efficacy. While exploration of radiosensitization strategies has vastly expanded with technological advances permitting the precise and conformal delivery of radiation, maximal clinical benefit derived from radiotherapy will require complementary discoveries that exploit molecularly-based vulnerabilities of tumor cells, as well as the assessment of investigational radiotherapy strategies in animal models that faithfully recapitulate radiobiologic responses of human cancers. To address these requirements, the purpose of this review is to underscore current and emerging concepts of molecularly targeted radiosensitizing strategies and highlight the utility of companion animal models for improving the predictive value of radiotherapy investigations.
RESUMEN
Surface enhanced Raman scattering (SERS) is a technique that demonstrates a number of advantages for the rapid, specific and sensitive detection of pathogenic microorganisms. In this review, an overview of label-free and label-based SERS approaches, including microfluidics, nucleic acid detection and immunoassays, for the multiplexed detection of pathogenic bacteria and viruses from the last decade will be discussed, as well as their transition into promising point-of-use detection technologies in industrial and medical settings.
Asunto(s)
Microfluídica , Espectrometría Raman , Bacterias , InmunoensayoRESUMEN
Correction for 'Surface enhanced Raman scattering for the multiplexed detection of pathogenic microorganisms: towards point-of-use applications' by Matthew E. Berry et al., Analyst, 2021, DOI: 10.1039/D1AN00865J.
RESUMEN
BACKGROUND: High-grade meningioma is an aggressive type of brain cancer that is often recalcitrant to surgery and radiotherapy, leading to poor overall survival. Currently, there are no FDA-approved drugs for meningioma, highlighting the need for new therapeutic options, but development is challenging due to the lack of predictive preclinical models. METHODS: To leverage the known overexpression of procaspase-3 in meningioma, PAC-1, a blood-brain barrier penetrant procaspase-3 activator, was evaluated for its ability to induce apoptosis in meningioma cells. To enhance the effects of PAC-1, combinations with either hydroxyurea or temozolomide were explored in cell culture. Both combinations were further investigated in small groups of canine meningioma patients and assessed by MRI, and the novel apoptosis tracer, [18F]C-SNAT4, was evaluated in patients treated with PAC-1 + HU. RESULTS: In meningioma cell lines in culture, PAC-1 + HU are synergistic while PAC-1 + TMZ show additive-to-synergistic effects. In canine meningioma patients, PAC-1 + HU led to stabilization of disease and no change in apoptosis within the tumor, whereas PAC-1 + TMZ reduced tumor burden in all three canine patients treated. CONCLUSIONS: Our results suggest PAC-1 + TMZ as a potentially efficacious combination for the treatment of human meningioma, and also demonstrate the utility of including pet dogs with meningioma as a means to assess anticancer strategies for this common brain tumor.
Asunto(s)
Neoplasias Meníngeas , Meningioma , Animales , Apoptosis , Caspasa 3 , Técnicas de Cultivo de Célula , Línea Celular Tumoral , Perros , Humanos , Hidroxiurea/farmacología , Neoplasias Meníngeas/tratamiento farmacológico , Neoplasias Meníngeas/veterinaria , Meningioma/tratamiento farmacológico , Meningioma/veterinaria , Temozolomida/farmacologíaRESUMEN
Dysbiosis of gut microbiota is associated with many pathologies, yet host factors modulating microbiota remain unclear. Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating condition of chronic pelvic pain often with comorbid urinary dysfunction and anxiety/depression, and recent studies find fecal dysbiosis in patients with IC/BPS. We identified the locus encoding acyloxyacyl hydrolase, Aoah, as a modulator of pelvic pain severity in a murine IC/BPS model. AOAH-deficient mice spontaneously develop rodent correlates of pelvic pain, increased responses to induced pelvic pain models, voiding dysfunction, and anxious/depressive behaviors. Here, we report that AOAH-deficient mice exhibit dysbiosis of gastrointestinal (GI) microbiota. AOAH-deficient mice exhibit an enlarged cecum, a phenotype long associated with germ-free rodents, and a "leaky gut" phenotype. AOAH-deficient ceca showed altered gene expression consistent with inflammation, Wnt signaling, and urologic disease. 16S sequencing of stool revealed altered microbiota in AOAH-deficient mice, and GC-MS identified altered metabolomes. Cohousing AOAH-deficient mice with wild-type mice resulted in converged microbiota and altered predicted metagenomes. Cohousing also abrogated the pelvic pain phenotype of AOAH-deficient mice, which was corroborated by oral gavage of AOAH-deficient mice with stool slurry of wild-type mice. Converged microbiota also alleviated comorbid anxiety-like behavior in AOAH-deficient mice. Oral gavage of AOAH-deficient mice with anaerobes cultured from IC/BPS stool resulted in exacerbation of pelvic allodynia. Together, these data indicate that AOAH is a host determinant of normal gut microbiota, and dysbiosis associated with AOAH deficiency contributes to pelvic pain. These findings suggest that the gut microbiome is a potential therapeutic target for IC/BPS.
Asunto(s)
Hidrolasas de Éster Carboxílico , Cistitis Intersticial , Microbioma Gastrointestinal , Dolor Pélvico , Animales , Humanos , Hidrolasas de Éster Carboxílico/genética , Hidrolasas de Éster Carboxílico/metabolismo , Cistitis Intersticial/metabolismo , Modelos Animales de Enfermedad , Disbiosis/complicaciones , Disbiosis/metabolismo , Microbioma Gastrointestinal/genética , Microbioma Gastrointestinal/fisiología , Inflamación/metabolismo , Dolor Pélvico/metabolismo , Dolor Pélvico/fisiopatología , Vejiga Urinaria/metabolismo , RatonesRESUMEN
As the capacity for generating large-scale molecular profiling data continues to grow, the ability to extract meaningful biological knowledge from it remains a limitation. Here, we describe the development of a new fixed repertoire of transcriptional modules, BloodGen3, that is designed to serve as a stable reusable framework for the analysis and interpretation of blood transcriptome data. The construction of this repertoire is based on co-clustering patterns observed across sixteen immunological and physiological states encompassing 985 blood transcriptome profiles. Interpretation is supported by customized resources, including module-level analysis workflows, fingerprint grid plot visualizations, interactive web applications and an extensive annotation framework comprising functional profiling reports and reference transcriptional profiles. Taken together, this well-characterized and well-supported transcriptional module repertoire can be employed for the interpretation and benchmarking of blood transcriptome profiles within and across patient cohorts. Blood transcriptome fingerprints for the 16 reference cohorts can be accessed interactively via: https://drinchai.shinyapps.io/BloodGen3Module/ .
Asunto(s)
Análisis Químico de la Sangre , Sangre , Perfilación de la Expresión Génica/métodos , Transcriptoma , Bacterias , Sangre/inmunología , Análisis Químico de la Sangre/métodos , Análisis por Conglomerados , Biología Computacional/métodos , Redes Reguladoras de Genes , HumanosRESUMEN
Purpose: The spatio-molecular distribution of choline and its metabolites in tumors is highly heterogeneous. Due to regulation of choline metabolism by hypoxic transcriptional signaling and other survival factors, we envisage that detection of such heterogeneity in patient tumors could provide the basis for advanced localized therapy. However, non-invasive methods to assess this phenomenon in patients are limited. We investigated such heterogeneity in Non-Small Cell Lung Cancer (NSCLC) with [18F]fluoromethyl-(1,2-2H4) choline ([18F]D4-FCH) and positron emission tomography/computed tomography (PET/CT). Experimental design: [18F]D4-FCH (300.5±72.9MBq [147.60-363.6MBq]) was administered intravenously to 17 newly diagnosed NSCLC patients. PET/CT scans were acquired concurrently with radioactive blood sampling to permit mathematical modelling of blood-tissue transcellular rate constants. Comparisons were made with biopsy-derived choline kinase-α (CHKα) expression and diagnostic [18F]fluorodeoxyglucose ([18F]FDG) scans. Results: Oxidation of [18F]D4-FCH to [18F]D4-fluorobetaine was suppressed (48.58±0.31% parent at 60 min) likely due to the deuterium isotope effect embodied within the design of the radiotracer. Early (5 min) and late (60 min) images showed specific uptake of tracer in all 51 lesions (tumors, lymph nodes and metastases) from 17 patients analyzed. [18F]D4-FCH-derived uptake (SUV60max) in index primary lesions (n=17) ranged between 2.87-10.13; lower than that of [18F]FDG PET [6.89-22.64]. Mathematical modelling demonstrated net irreversible uptake of [18F]D4-FCH at steady-state, and parametric mapping of the entire tumor showed large intratumorally heterogeneity in radiotracer retention, which is likely to have influenced correlations with biopsy-derived CHKα expression. Conclusions: [18F]D4-FCH is detectable in NSCLC with large intratumorally heterogeneity, which could be exploited in the future for targeting localized therapy.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/diagnóstico por imagen , Colina Quinasa/metabolismo , Colina/análogos & derivados , Deuterio/química , Neoplasias Pulmonares/diagnóstico por imagen , Administración Intravenosa , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Colina/administración & dosificación , Colina/química , Colina/farmacología , Estudios de Factibilidad , Femenino , Humanos , Neoplasias Pulmonares/metabolismo , Metástasis Linfática , Masculino , Persona de Mediana Edad , Modelos Teóricos , Tomografía Computarizada por Tomografía de Emisión de Positrones , Estudios Prospectivos , Sensibilidad y EspecificidadRESUMEN
We present Knowledge Engine for Genomics (KnowEnG), a free-to-use computational system for analysis of genomics data sets, designed to accelerate biomedical discovery. It includes tools for popular bioinformatics tasks such as gene prioritization, sample clustering, gene set analysis, and expression signature analysis. The system specializes in "knowledge-guided" data mining and machine learning algorithms, in which user-provided data are analyzed in light of prior information about genes, aggregated from numerous knowledge bases and encoded in a massive "Knowledge Network." KnowEnG adheres to "FAIR" principles (findable, accessible, interoperable, and reuseable): its tools are easily portable to diverse computing environments, run on the cloud for scalable and cost-effective execution, and are interoperable with other computing platforms. The analysis tools are made available through multiple access modes, including a web portal with specialized visualization modules. We demonstrate the KnowEnG system's potential value in democratization of advanced tools for the modern genomics era through several case studies that use its tools to recreate and expand upon the published analysis of cancer data sets.
Asunto(s)
Algoritmos , Nube Computacional , Minería de Datos/métodos , Genómica/métodos , Programas Informáticos , Análisis por Conglomerados , Biología Computacional/métodos , Análisis de Datos , Conjuntos de Datos como Asunto , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Humanos , Conocimiento , Aprendizaje Automático , Metabolómica/métodosRESUMEN
During the process of acting, actors have to embody the characters that they are portraying by changing their vocal and gestural features to match standard conceptions of the characters. In this experimental study of acting, we had professional actors portray a series of stock characters (e.g., king, bully, lover), which were organized according to a predictive scheme based on the 2 orthogonal personality dimensions of assertiveness and cooperativeness. We measured 12 prosodic features of the actors' vocal productions, as related to pitch, loudness, timbre, and duration/timing. The results showed a significant effect of character assertiveness on all 12 vocal parameters, but a weaker effect of cooperativeness on fewer vocal parameters. These findings comprise the first experimental analysis of vocal gesturing during character portrayal in actors and demonstrate that actors reliably manipulate prosodic cues in a contrastive manner to differentiate characters based on their personality traits. (PsycINFO Database Record (c) 2019 APA, all rights reserved).